Effect of sivelestat, a neutrophil elastase inhibitor on cardiac surgical patients after cardiopulmonary bypass

Effect of sivelestat, a neutrophil elastase inhibitor on cardiac surgical patients after cardiopulmonary bypass - Effect of sivelestat, a neutrophil elastase inhibitor on cardiac surgical patients after cardiopulmonary bypass

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036507

Enrollment

Registered

2019-04-14

Start date

2004-01-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac and aortic disease

Interventions

0.9 % saline 2ml/hr for 24 hours sivelestat 0.2mg/kg/hr for 24 hours

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: cardiac surgical patients undergoing cardiopulmonary bypass

Exclusion criteria

Exclusion criteria: shock, pulmonary edema, liver dysfunction

Design outcomes

Primary

Measure	Time frame
perioperative cytokine in bronchial bronchiolar lavage fluid, pulmonary function, oxygenation.	—

Secondary

Measure	Time frame
myocardial injury, hemodynamics, perioperative cytokine in blood	—

Countries

Japan

Contacts

Public ContactMasahiro Fujii

Nippon Medical School Cardiovascular surgery

mfujii-cvs@umin.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026